Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery

Journal of Neuro-Oncology

Volumn 95, Issue 3, 2009, Pages 331-342

  Oh, Seunguk ^a   Ohlfest, John R ^b   Todhunter, Deborah A ^a   Vallera, Vincent D ^a   Hall, Walter A ^c   Chen, Hua ^a   Vallera, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Carcinoma; Cytotoxin; Diphtheria toxin; EGF; Fusion protein; Glioblastoma; IL 13; Immunotoxin; Xenograft model

Indexed keywords

AMINO ACID; CYTOTOXIN; DIPHTHERIA TOXIN; DTEGF13; EPITHELIAL GROWTH FACTOR; FIREFLY LUCIFERASE; GROWTH FACTOR; INTERLEUKIN 13; LIGAND; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; NONHUMAN; NUDE RAT; RAT; REPORTER GENE;

ANIMALS; ANTIBODY SPECIFICITY; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, REPORTER; GLIOBLASTOMA; HUMANS; IMMUNOGLOBULIN G; LIGANDS; LIVER; LUCIFERASES; NEOPLASM TRANSPLANTATION; RATS; RATS, NUDE; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70450253409     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9932-2     Document Type: Article

References (52)

1. AM Omuro S Faivre E Raymond 2007 Lessons learned in the development of targeted therapy for malignant gliomas Mol Cancer Ther 6 1909 1919 10.1158/1535-7163.MCT-07-0047 10.1158/1535-7163.MCT-07-0047 17620423 (Pubitemid 47052481)
2. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 10.1056/NEJMoa043330 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
3. DA Todhunter WA Hall DA Vallera, et al. 2004 A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model Protein Eng Des Sel 17 157 164 10.1093/protein/gzh023 10.1093/protein/gzh023 15047912 (Pubitemid 38477742)
4. Vallera DA, Chen H, Sicheneder AR et al (2009) Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res. doi: 10.1016/j.leukres.2009.02.006
5. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA (2007) Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 13:3058-3067. doi: 10.1158/1078-0432.CCR-06-2454 (Pubitemid 46849583)
6. BJ Stish S Oh DA Vallera, et al. 2008 Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model J Neurooncol 87 51 61 10.1007/s11060-007-9499-8 10.1007/s11060-007-9499-8 18084721
7. M Schmidt NE Hynes B Groner W Wels 1995 A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor Int J Cancer 65 538 546 10.1002/(SICI)1097-0215(19960208)65:4<538::AID-IJC24>3.0.CO;2-4 10.1002/(SICI)1097-0215(19960208)65:4<538::AID-IJC24>3.0.CO;2-4
8. JS Dukecohan C Morimoto SF Schlossman 1993 Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29 Transplantation 56 1188 1196 (Pubitemid 23348699)
9. G Shen J Li ES Vitetta 1994 A bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells, but not T cells in vitro and shows both A chain-mediated and LAK-T mediated killing J Immunol 152 2368 2376 8133047
10. BJ Stish H Chen A Panoskaltsis-Mortari DA Vallera 2007 A bispecific recombinant cytotoxin (DTEGF13) targeting human IL-13 and EGF receptors in a mouse xenograft model of prostate cancer Clin Cancer Res 13 6486 6493 10.1158/1078-0432.CCR-07-0938 10.1158/1078-0432.CCR-07-0938 17975161 (Pubitemid 350075039)
11. DA Vallera Y Shu BJ Stish, et al. 2008 Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model Gut 57 634 641 10.1136/gut.2007.137802 10.1136/gut.2007.137802 18222985 (Pubitemid 351579977)
12. W Debinski NI Obiri RK Puri, et al. 1995 Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin Clin Cancer Res 1 1253 1258 9815919
13. W Debinski DM Gibo GY Gillespie, et al. 1999 Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas Clin Cancer Res 5 985 990 10353730 (Pubitemid 29233211)
14. W Debinski B Slagle GY Gillespie, et al. 2000 Expression of a restrictive receptor for interleukin 13 is associated with glial transformation J Neurooncol 48 103 111 10.1023/A:1006446426611 10.1023/A:1006446426611 11083073 (Pubitemid 30779823)
15. SR Husain BH Joshi RK Puri, et al. 2001 Interleukin-13 receptor as a unique target for anti-glioblastoma therapy Int J Cancer 92 168 175 10.1002/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N 10.1002/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N 11291041 (Pubitemid 32225365)
16. SR Husain RK Puri 2003 Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside J Neurooncol 65 37 48 10.1023/A:1026242432647 10.1023/A:1026242432647 14649884 (Pubitemid 37441313)
17. O Engebraaten GO Hjortland O Fodstad, et al. 2002 Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals Int J Cancer 97 846 852 10.1002/ijc.10137 10.1002/ijc.10137 11857366 (Pubitemid 34106343)
18. TF Liu PD Hall AE Frankel, et al. 2005 Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice Clin Cancer Res 11 329 334 15671563
19. TF Liu MC Willingham AE Frankel, et al. 2003 Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells Bioconjug Chem 14 1107 1114 10.1021/bc034111+ 10.1021/bc034111+ 14624623 (Pubitemid 37449037)
20. TF Liu SB Tatter AE Frankel, et al. 2003 Growth factor receptor expression varies among high grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy Mol Cancer Ther 2 783 787 12939468
21. M Yamaizumi E Mekada Y Okada, et al. 1978 One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell Cell 15 245 250 10.1016/0092-8674(78)90099-5 10.1016/0092-8674(78)90099-5 699044
22. DP Williams CE Snider JR Murphy, et al. 1990 Structure/function analysis of interleukin-2-toxin (DAB486-IL-2) Fragment B sequences required for the delivery of fragment A to the cytosol of target cells J Biol Chem 265 11885 11889 2195027
23. RJ Collier 1975 Diphtheria toxin: mode of action and structure Bacteriol Rev 39 54 85 164179
24. DW Laske RJ Youle EH Oldfield 1997 Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors Nat Med 3 1362 1368 10.1038/nm1297-1362 10.1038/nm1297-1362 9396606 (Pubitemid 28011036)
25. JR Ohlfest ZL Demorest Y Motooka I Vengco S Oh E Chen FA Scappaticci RJ Saplis SC Ekker WC Low AB Freese DA Largaespada 2005 Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma Mol Ther 5 778 788 10.1016/j.ymthe.2005.07.689 10.1016/j.ymthe.2005.07.689 (Pubitemid 41614473)
26. DA Vallera D Todhunter H Chen, et al. 2005 Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice Leuk Res 29 331 341 10.1016/j.leukres.2004.08.006 10.1016/j.leukres.2004.08.006 15661270 (Pubitemid 40127061)
27. DA Benaron PR Contag CH Contag 1997 Imaging brain and function, infection and gene expression in the body using light Philos Trans R Soc Lond B Biol Sci 352 755 761 10.1098/rstb.1997.0059 10.1098/rstb.1997.0059 9232865 (Pubitemid 27354108)
28. E Rustamzadeh WA Hall DA Vallera, et al. 2007 Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice Int J Cancer 120 411 419 10.1002/ijc.22278 10.1002/ijc.22278 17075792 (Pubitemid 44956855)
29. E Rustamzadeh WA Hall DA Vallera, et al. 2006 Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice Int J Cancer 118 2594 2601 10.1002/ijc.21647 10.1002/ijc.21647 16358262
30. DA Vallera RC Ash RJ Youle, et al. 1983 Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies Science 222 512 515 10.1126/science.6353579 10.1126/science.6353579 6353579
31. RJ Kreitman DR Squires I Pastan, et al. 2005 Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies J Clin Oncol 23 6719 6729 10.1200/JCO.2005.11.437 10.1200/JCO.2005.11.437 16061911 Sep 20 (Pubitemid 46190267)
32. MM Souweidane G Occhiogrosso MA Edgar, et al. 2004 Interstitial infusion of IL-13-PE38QQR in the rat brain stem J Neurooncol 67 287 293 10.1023/B:NEON.0000024219.47447.91 10.1023/B:NEON.0000024219.47447.91 15164984 (Pubitemid 39137359)
33. AT Myklebust A Godal O Fodstad 1994 Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer Cancer Res 54 2146 2150 8174121
34. GO Hjortland SS Garman-Vik O Engebraaten, et al. 2004 Immunotoxin treatment targeted to the high-molecular weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme J Neurosurg 100 320 327 10.3171/jns.2004.100.2.0320 15086240
35. AN McKenzie G Zurawski 1995 Interleukin-13: characterization and biologic properties Cancer Treat Res 80 367 378 8821586
36. TC Elleman T Domagala M Nerrie, et al. 2001 Identification of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain Biochemistry 40 8930 8939 10.1021/bi010037b 10.1021/bi010037b 11467954 (Pubitemid 32709526)
37. AT Parsa I Chakrabarti JN Bruce, et al. 2000 Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy Neurosurgery 47 993 999 10.1097/00006123-200010000-00050 10.1097/00006123- 200010000-00050 11014444
38. ES Vitetta 2000 Immuntoxin and vascular leak syndrome Cancer J 6 S218 S224 10874491
39. R Baluna ES Vitetta 1999 An in vivo model to study of immuntoxin-induced vascular leak syndrome in human tissue J Immunother 22 41 47 10.1097/00002371-199901000-00006 10.1097/00002371-199901000-00006 9924698 (Pubitemid 29042289)
40. M Kioi SR Husain RK Puri, et al. 2006 Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy Technol Cancer Res Treat 5 239 250 16700620
41. M Onda R Beers L Xiang S Nagata QC Wang I Pastan 2008 An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes Proc Natl Acad Sci USA 105 11311 11316 10.1073/pnas.0804851105 10.1073/pnas.0804851105 18678888
42. Oh S, Ohlfest JR, Todhunter DA, Vallera VD, Hall WA, Chen H, Vallera DA (2009) Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin DTEGF13 and convection enhanced delivery. J Neurooncol (in press)
43. M Juweid R Neumann JN Weinstein, et al. 1992 Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for binding site barrier Cancer Res 52 5144 5153 1327501
44. T Saga RD Neumann JN Weinstein, et al. 1995 Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier Proc Natl Acad Sci USA 92 8999 9003 10.1073/pnas.92.19.8999 10.1073/pnas.92.19.8999 7568060
45. RA Kroll MA Pagel EA Neuwelt, et al. 1996 Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor Neurosurgery 38 746 752 10.1097/00006123-199604000-00024 10.1097/00006123-199604000-00024 8692395
46. JH Sampson G Akabani GE Archer, et al. 2008 Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumor Neurooncology 10 320 329 10.1215/15228517-2008-012
47. S Kunwar MD Prados SM Chang, et al. 2007 Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group J Clin Oncol 25 837 844 10.1200/JCO.2006.08.1117 10.1200/JCO.2006.08.1117 17327604 (Pubitemid 350002884)
48. S Oh R Odland SR Wilson, et al. 2007 Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter J Neurosurg 107 568 577 10.3171/JNS-07/09/0568 10.3171/JNS-07/09/0568 17886557 (Pubitemid 47451041)
49. C Sung RL Dedrick RJ Youle, et al. 1993 The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography Cancer Res 53 2092 2099 8481911
50. RK Jain 1990 Vascular and interstitial barriers to delivery of therapeutic agents in tumors Cancer Metastasis Rev 9 253 266 10.1007/BF00046364 10.1007/BF00046364 2292138
51. K Fujimori DG Covell JN Weinstein, et al. 1990 A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier J Nucl Med 31 1191 1198 2362198
52. G Zurawski JE de Vries 1994 Interleukin 13 elicits a subset of the activities of its close relative interleukin 4 Stem Cells 12 169 174 10.1002/stem.5530120204 7911047